JPH0331716B2 - - Google Patents
Info
- Publication number
- JPH0331716B2 JPH0331716B2 JP57026170A JP2617082A JPH0331716B2 JP H0331716 B2 JPH0331716 B2 JP H0331716B2 JP 57026170 A JP57026170 A JP 57026170A JP 2617082 A JP2617082 A JP 2617082A JP H0331716 B2 JPH0331716 B2 JP H0331716B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- parts
- ampicillin
- dioxo
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 78
- 239000000203 mixture Substances 0.000 claims description 37
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 35
- 229960000723 ampicillin Drugs 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000011541 reaction mixture Substances 0.000 claims description 21
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 239000002585 base Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 150000004820 halides Chemical class 0.000 claims description 10
- RBKMMJSQKNKNEV-RITPCOANSA-N penicillanic acid Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2CC(=O)N21 RBKMMJSQKNKNEV-RITPCOANSA-N 0.000 claims description 8
- -1 piperazinocarbonyl halide Chemical class 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 6
- 239000002198 insoluble material Substances 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000012452 mother liquor Substances 0.000 claims description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- 239000011877 solvent mixture Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims 1
- 150000008041 alkali metal carbonates Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 11
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 7
- 239000013078 crystal Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000000571 coke Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229960003311 ampicillin trihydrate Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Chemical group 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Description
【発明の詳細な説明】
本発明は6−置換ペニシラン酸の改良された製
造方法に関する。更に詳細には本発明は式()
〔式中、RはC1〜C4アルキルである〕
の6−〔D(−)−α−(4−アルキル−2,3−ジ
オキソ−1−ピペラジノカルボキシルアミノ)フ
エニルアセトアミド〕ペニシラン酸の改良された
製造方法に関する。これらの化合物は肺炎
(pneumonia)、腹膜炎(peritonitis)及び血液系
感染症の処置のための抗生物質として有用であ
る。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an improved process for producing 6-substituted penicillanic acids. More specifically, the present invention is based on the formula () 6-[D(-)-α-(4-alkyl-2,3-dioxo-1-piperazinocarboxylamino)phenylacetamide]penisilane [wherein R is C1 - C4 alkyl] This invention relates to an improved method for producing acids. These compounds are useful as antibiotics for the treatment of pneumonia, peritonitis, and blood system infections.
Saikawaらは、米国特許第4112090号におい
て、式()
〔式中、RはC1〜C4アルキである〕
の4−C1〜C4アルキル−2,3−ジオキソ−1
−ピペラジノカルボニルクロライド式()
によつて表わされる6−〔D(−)−α−アミノ−
フエニルアセトアミド〕ペニシラン酸三水和物と
反応させることによる式()の6−置換ペニシ
ラン酸の製造方法を開示している。 Saikawa et al., in U.S. Patent No. 4,112,090, describe the formula () 4- C1 - C4 alkyl-2,3-dioxo-1 [wherein R is C1 - C4 alkyl]
−Piperazinocarbonyl chloride formula () 6-[D(-)-α-amino-
phenylacetamide] A method for preparing 6-substituted penicillanic acids of formula () by reaction with penicillanic acid trihydrate is disclosed.
式()の無水形を以後アンピシリン
(ampicillin)と称する。上記特許の実施例23に
おいては、化合物()1重量部当り10重量部の
水及び4.5重量部の酢酸エチルの混合物中の化合
物()の懸濁液を2℃まで冷却し、炭酸カリウ
ム2モル当量と2〜3℃で数分間混合し、Rがメ
チルの式()の化合物1モル割合を2〜3℃で
10分間に亘つて混合し、そして該温度で更に15分
間反応させている。この反応混合物を清澄化させ
ていくらかの不溶物を除去し、母液に元々仕込ん
だ化合物()1重量部当り18重量部の酢酸エチ
ルをさらに混合する。次いで得られる混合物を
2NHCl1モル当量で20〜22℃で5分間に亘つて酸
性にし、20〜22℃で5時間攪拌する。沈殿した結
晶を集め、水及びイソプロパノールで連続的に洗
浄し、乾燥して6−〔D(−)−α−(4−メチル−
2,3−ジオキソ−1−ピペラジノカルボニルイ
ミノ)フエニルアセトアミド〕ペニシラン酸の二
水和物が75.4%の収率で得られる。同様の実施例
において、式()の化合物がR=エチルである
場合、6−〔D(−)−α−(4−エチル−2,3−
ジオキソ−1−ピペラジノカルボニルアミノ)フ
エニルアセトアミド〕ペニシラン酸の一水和物が
84.8%の収率で得られる。 The anhydrous form of formula () is hereinafter referred to as ampicillin. In Example 23 of the above patent, a suspension of compound () in a mixture of 10 parts by weight of water and 4.5 parts by weight of ethyl acetate per 1 part by weight of compound () was cooled to 2°C, and 2 mol of potassium carbonate was added. 1 molar proportion of the compound of formula () where R is methyl at 2-3°C.
Mix for 10 minutes and react at temperature for an additional 15 minutes. The reaction mixture is clarified to remove some insoluble materials and is further mixed with 18 parts by weight of ethyl acetate per part by weight of compound () originally charged in the mother liquor. Then the resulting mixture
Acidify with 1 molar equivalent of 2NHCl at 20-22°C for 5 minutes and stir at 20-22°C for 5 hours. The precipitated crystals were collected, washed successively with water and isopropanol, and dried to give 6-[D(-)-α-(4-methyl-
The dihydrate of 2,3-dioxo-1-piperazinocarbonylimino)phenylacetamido]penicillanic acid is obtained in a yield of 75.4%. In a similar example, when the compound of formula () is R=ethyl, 6-[D(-)-α-(4-ethyl-2,3-
dioxo-1-piperazinocarbonylamino)phenylacetamide] penicillanic acid monohydrate
Obtained with a yield of 84.8%.
得られる収率をかなり増大させる改良された方
法が必要である。本発明はそのような方法を提供
するものであり、最終収率は約95%である。 There is a need for improved methods that significantly increase the yields obtained. The present invention provides such a method, with a final yield of about 95%.
本発明は、4−C1〜C4アルキル−2,3−ジ
オキソ−1−ピペラジノカルボニルハライドを塩
基の存在下に酢酸エチル及び水の混合物中のアン
ピシリンの溶液又は懸濁液に添加して反応混合物
を生成せしめ、得られた混合物を反応が完結する
まで攪拌し、反応混合物を酸性にし、そしてそれ
から結晶生成物を回収することから成る式()
の6−〔D(−)−α−(4−C1〜C4アルキル−2,
3−ジオキソ−1−ピペラジノカルボニルアミ
ノ)−フエニルアセトアミド〕ペニシラン酸の製
造方法におおいて、
(1) アンピシリン1重量部当り水約9〜12重量部
及び酢酸エチル約0.5〜8重量部からなる溶媒
混合物中の、約1モル割合のアンピシリン及び
適当量の適当な塩基の攪拌懸濁液に、約10〜25
℃で少くとも30分間に亘り、約6〜8.3のPHを
維持しながら、4−C1〜C4アルキル−2,3
−ジオキソ−1−ピペラジノカルボニルハライ
ド約1〜1.5モル割合を添加し;
(2) 工程(1)の4−C1〜C4アルキル−2,3−ジ
オキソ−1−ピペラジノーカルボニルハライド
の添加が完了したら、反応混合物を約10〜25℃
で少くとも15分間更に攪拌し;
(3) この反応混合物に、工程(1)で仕込んだアンピ
シリン1重量部当りそれぞれ約0.05〜0.2重量
部の活性炭及び過助剤を添加し、そして得ら
れる混合物を約約10〜25℃で少くとも10分間攪
拌し;
(4) 得られる混合物を清澄化させ、そして工程(1)
で仕込んだアンピシリン1重量部当り約0.6〜
2.5重量部の水で不溶性物質を洗浄し;
(5) 工程(4)で得た母液及び洗浄液を、工程(1)で仕
込んだアンピシリン1重量部当り約2〜12.5重
量部の酢酸エチルと一緒にし、但し工程(1)及び
(5)で使用する酢酸エチルの全量は該アンピシリ
ン1重量部当り約10〜13重量部であり、そして
得られる混合物を約15〜25℃に加温し;
(6) 工程(5)で得た混合物を約15〜25℃において約
2.0〜2.5のPHまで酸性にし;そして
(7) 酢酸にした混合物を約15〜25℃で少くとも1
時間攪拌した後、得られる結晶性の遊離酸を集
め;そして
(8) この遊離酸を随時製薬学的に許容しうる塩に
転化する、
ことから成る6−〔D(−)−α−(4−C1〜C4ア
ルキル−2,3−ジオキソ−1−ピペラジノカル
ボニルアミノ)−フエニルアセトアミド〕ペニシ
ラン酸の改良された製造方法を提供する。 The present invention comprises adding 4- C1 - C4 alkyl-2,3-dioxo-1-piperazinocarbonyl halide to a solution or suspension of ampicillin in a mixture of ethyl acetate and water in the presence of a base. a reaction mixture, stirring the resulting mixture until the reaction is complete, acidifying the reaction mixture, and then recovering the crystalline product.
6-[D(-)-α-(4-C 1 to C 4 alkyl-2,
In the method for producing penicillanic acid (3-dioxo-1-piperazinocarbonylamino)-phenylacetamide, (1) about 9 to 12 parts by weight of water and about 0.5 to 8 parts by weight of ethyl acetate per 1 part by weight of ampicillin; A stirred suspension of about 1 molar proportion of ampicillin and an appropriate amount of a suitable base in a solvent mixture consisting of about 10 to 25
4-C1 to C4 alkyl -2,3 while maintaining a pH of about 6 to 8.3 for at least 30 minutes at °C.
-Adding about 1 to 1.5 molar proportion of dioxo-1-piperazinocarbonyl halide; (2) 4- C1 to C4 alkyl-2,3-dioxo-1-piperazinocarbonyl halide of step (1); Once the addition is complete, heat the reaction mixture to approximately 10-25 °C.
(3) To this reaction mixture, add about 0.05 to 0.2 parts by weight of activated carbon and super-aid agent per 1 part by weight of ampicillin charged in step (1), and the resulting mixture (4) Clarify the resulting mixture and perform step (1).
Approximately 0.6 to 1 part by weight of ampicillin prepared with
Wash the insoluble material with 2.5 parts by weight of water; (5) Combine the mother liquor and washing liquid obtained in step (4) with about 2 to 12.5 parts by weight of ethyl acetate per 1 part by weight of ampicillin charged in step (1). However, step (1) and
The total amount of ethyl acetate used in step (5) is about 10 to 13 parts by weight per part of ampicillin, and the resulting mixture is heated to about 15 to 25°C; The mixture was heated to about 15-25°C.
acidify to a pH of 2.0-2.5; and (7) acetic acid mixture at about 15-25°C.
6-[D(-)-α-( An improved method for producing 4- C1 - C4 alkyl-2,3-dioxo-1-piperazinocarbonylamino)-phenylacetamide penicillanic acid is provided.
本発明の方法は式()の生成物を約95%の収
率で与える。 The process of the invention provides the product of formula () in about 95% yield.
本発明の方法を行なう場合、アンピシリン1重
量部当り約9〜12、好ましくは約10〜11重量部の
水及び約0.5〜8、好ましくは約4〜6重量部の
酢酸エチルを与えるような量で、アンピシリンの
水及び酢酸エチルの混合物中の撹拌懸濁液を調製
する。このアンピシリンは化合物()の無水形
として定義される。 When carrying out the process of the invention, amounts are such as to provide about 9 to 12, preferably about 10 to 11 parts by weight of water and about 0.5 to 8, preferably about 4 to 6 parts by weight of ethyl acetate per part by weight of ampicillin. A stirred suspension of ampicillin in a mixture of water and ethyl acetate is prepared. This ampicillin is defined as the anhydrous form of the compound ().
この混合物に適当量の適当な塩基を添加する。
本発明の高収率を保証するためには、塩基の量
は、最初の混合物のPHを約6〜8.3、好ましくは
約6.5〜8にするのに、及び4−C1〜C4アルキル
−2,3−ジオキソ−1−ピペラジノカルボニル
ハライドの続く添加中、該PH範囲を維持するのに
十分でなければならない。好適な塩基の添加法
は、最初の混合物に、仕込んだアンピシリン1モ
ル当り約2.4〜3.0、好ましくは約2.5〜2.7モル当
量の塩基、例えば炭酸水素ナトリウム又はカリウ
ムを導入することである。この方法の場合、カル
ボニルハライドの続く添加はPHの変化をもたらさ
ない。或いは、例えば水酸化カリウム又はナトリ
ウム或いは炭酸カリウム又はナトリウムのような
塩基も、最初の混合物を約6〜8.3、好ましくは
約6.5〜8のPHにするために使用することができ
るが、以後カルボニルハライドの続く添加中、PH
を監視しそしてこのPH範囲を維持すべく注意を払
わなければならない。PHは直接な測定及び適当な
酸又は塩基の添加によつて監視でき、或いはPHは
最初の反応系に適当な無干渉性緩衝系を添加する
ことにより適当な範囲に維持することができる。
この場合、緩衝系は当業者によつて容易に決定さ
れる。 Add the appropriate amount of a suitable base to this mixture.
To ensure high yields of the present invention, the amount of base should be sufficient to bring the pH of the initial mixture to about 6-8.3, preferably about 6.5-8 , and 4-C1- C4 alkyl- It must be sufficient to maintain the PH range during the subsequent addition of 2,3-dioxo-1-piperazinocarbonyl halide. A preferred method of adding base is to introduce into the initial mixture about 2.4 to 3.0, preferably about 2.5 to 2.7, molar equivalents of base, such as sodium or potassium bicarbonate, per mole of ampicillin charged. With this method, subsequent addition of carbonyl halide does not result in a change in PH. Alternatively, a base such as potassium or sodium hydroxide or potassium or sodium carbonate can also be used to bring the initial mixture to a pH of about 6-8.3, preferably about 6.5-8, but then the carbonyl halide During the subsequent addition of PH
must be monitored and care must be taken to maintain this PH range. The PH can be monitored by direct measurement and addition of a suitable acid or base, or the PH can be maintained within a suitable range by adding a suitable non-interfering buffer system to the initial reaction system.
In this case, the buffer system is easily determined by a person skilled in the art.
最初の混合物を約10〜25℃、好しくは約12〜18
℃の温度に調節し、これに式
〔式中、RはC1〜C4アルキルであり、そして
Xは弗素、塩素、臭素又は沃素である〕
の4−C1〜C4アルキル−2,3−ジオキソ−1
−ピペラジノカルボニルハライド約1〜1.5、好
ましくは約1.05〜1.15モル割合を添加する。次い
で反応混合物を上述の温度及び約6〜8.3、好ま
しくは約6.5〜8のPHに維持しながら、式の化
合物を、少くとも30分間、好ましくは約40〜60分
間に亘つて混合物に添加する。好適な方法では、
式の化合物は4−C1〜C4アルキル−2,3−
ジオキソ−1−ピペラジノカルボニルクロライド
であり;4−エチル−2,3−ジオキソ−1−ピ
ペラジノカルボニルクロライドが特に好適であ
る。 The initial mixture is heated to about 10-25℃, preferably about 12-18℃
Adjust the temperature to ℃ and apply the formula to this 4- C1 - C4 alkyl-2,3-dioxo-1 in which R is C1 - C4 alkyl and X is fluorine, chlorine, bromine or iodine.
- Adding about 1 to 1.5, preferably about 1.05 to 1.15 molar proportions of piperazinocarbonyl halide. A compound of formula is then added to the mixture over a period of at least 30 minutes, preferably about 40 to 60 minutes, while the reaction mixture is maintained at the above temperature and pH of about 6 to 8.3, preferably about 6.5 to 8. . In a preferred method,
The compound of the formula is 4-C 1 -C 4 alkyl-2,3-
Dioxo-1-piperazinocarbonyl chloride; 4-ethyl-2,3-dioxo-1-piperazinocarbonyl chloride is particularly preferred.
得られる混合物を、式の化合物の添加が完了
した後、該温度及びPHにおいて少くとも15分間、
好ましくは約20〜30分間撹拌する。次いで反応混
合物を、元々仕込んだアンピシリン1重量部当り
約0.05〜0.2、好ましくは約0.08〜0.1重量部の活
性炭例えば活性炭又はRB型活性炭(Puttsburgh
Coke and Chemical Co.)、及び約0.05〜0.2、好
ましくは約0.1〜0.15重量部の過助剤例えば
Hyflo
Super−Cel(Johns−Manville Sales
Corp.)で処理する。次いで得られる混合物を該
温度で少くとも10分間、好ましくは約15〜20分間
撹拌する。 The resulting mixture is heated at the temperature and pH for at least 15 minutes after the addition of the compound of formula is complete.
Stir preferably for about 20-30 minutes. The reaction mixture is then treated with about 0.05 to 0.2, preferably about 0.08 to 0.1 parts by weight of activated carbon, such as activated carbon or RB type activated carbon (Puttsburgh type activated carbon), per part by weight of ampicillin originally charged.
Coke and Chemical Co.) and about 0.05 to 0.2, preferably about 0.1 to 0.15 parts by weight of a super-aid, e.g.
Hyflo Super−Cel (Johns−Manville Sales
Corp.). The resulting mixture is then stirred at that temperature for at least 10 minutes, preferably about 15-20 minutes.
次いで反応混合物から、当業者には公知の常法
によつて不溶物質を分離する。好適な分離法は
過である。過残渣を、元々仕込んだアンピシリ
ン1重量部当り約0.6〜2.5、好ましくは約1.0〜
1.2重量部の水で洗浄する。次いで洗浄液を、
過から得た母液と一緒にし、これに元々仕込んだ
アンピシリン1重量当り約2〜12.5、好ましくは
約6〜7重量部の酢酸エチルを添加する。但し
元々の反応混合物中に存在する酢酸エチルを含む
酢酸エチルの全使用量は、元々仕込んだアンピシ
リン1重量部当り約10〜13、好ましくは約11〜12
重量部である。 The reaction mixture is then separated from insoluble materials by conventional methods known to those skilled in the art. A preferred separation method is filtration. The excess residue is about 0.6 to 2.5, preferably about 1.0 to 1.0, per 1 part by weight of ampicillin originally charged.
Wash with 1.2 parts by weight of water. Then add the cleaning solution,
About 2 to 12.5, preferably about 6 to 7 parts by weight of ethyl acetate per weight of ampicillin originally charged is added thereto. However, the total amount of ethyl acetate used, including ethyl acetate present in the original reaction mixture, is about 10 to 13, preferably about 11 to 12, per part by weight of ampicillin originally charged.
Parts by weight.
得られる混合物を約15〜25℃、好ましくは18〜
22℃に加温し、該温度において稀鉱酸、例えば2
〜5Nの塩酸又は硫酸で約2.0〜2.5、好ましくは約
2.2〜2.3のPHまで酸性にする。 The resulting mixture is heated to about 15-25°C, preferably 18-25°C.
Warm to 22°C and add at that temperature a dilute mineral acid, e.g.
~5N hydrochloric acid or sulfuric acid about 2.0 to 2.5, preferably about
Acidify to a PH of 2.2-2.3.
次いでこの酸性にした混合物を該温度で少くと
も1時間、好ましくは約2〜3時間撹拌し、得ら
れる結晶を当業者には周知の方法、例えば過又
は遠心分離によつて集める。次いで結晶を水洗
し、乾燥して所望の遊離酸生成物を約94〜96%の
収率で得る。この遊離酸はいろいろな程度に水和
されていてもよい。 The acidified mixture is then stirred at said temperature for at least 1 hour, preferably about 2-3 hours, and the resulting crystals are collected by methods well known to those skilled in the art, such as by filtration or centrifugation. The crystals are then washed with water and dried to yield the desired free acid product in about 94-96% yield. The free acid may be hydrated to varying degrees.
酢酸エチルの溶媒としての選択は、結晶工程中
の酢酸エチルの相対濃度と同様に臨界的である。
反応及び結晶工程中のPHの制御もまた臨界的であ
る。これらの因子の上述した範囲の変動は、最終
収率を低下させ、或いは最終生成物の分離及び精
製を時間のかかる且つ費用のかかるものとする劣
つた結晶構造の、時には全然結晶構造を有さない
非晶質の物体を生成する。 The choice of ethyl acetate as a solvent is critical, as is the relative concentration of ethyl acetate during the crystallization step.
Control of PH during the reaction and crystallization process is also critical. Variation of these factors in the ranges mentioned above may reduce the final yield or result in products having a poor crystal structure, sometimes no crystal structure at all, making the separation and purification of the final product time-consuming and expensive. No amorphous objects are produced.
上で得た遊離酸は、当業者に周知の方法によつ
て製薬学的に許容しうる塩に転化することができ
る。この製薬学的に許容しうる塩は例えばアルカ
リ金属、アルカリ土類金属、アンモニウム、N−
メチルグルカミンなどを含む。ナトリウム塩が好
適であり、好ましくは上述の方法で得られる式
()の化合物を水中で炭酸水素ナトリウムの当
量で処理することによつて得ることができる。 The free acid obtained above can be converted into a pharmaceutically acceptable salt by methods well known to those skilled in the art. The pharmaceutically acceptable salts include, for example, alkali metal, alkaline earth metal, ammonium, N-
Contains methylglucamine. The sodium salt is preferred and can be obtained by treating the compound of formula (), preferably obtained by the method described above, with an equivalent of sodium bicarbonate in water.
本明細書において、断わらない限りすべての温
度及び温度範囲はセツ氏によるものとする。百分
率又は(%)は重量%であり、モルはgモルであ
る。また当量は、限定された重量又は容量のモル
に関し、製造例又は実施例で示す前記又は後記反
応物のモル数に等しい反応物のモル量を意味す
る。 In this specification, unless otherwise specified, all temperatures and temperature ranges are those of Setsu. Percentages or (%) are weight % and moles are g moles. In addition, the term "equivalent" refers to a molar amount of a reactant that is equal to the number of moles of the above-mentioned or below-mentioned reactant shown in the Preparation Examples or Examples, with respect to moles of a limited weight or volume.
本発明はまた、
(1) アンピシリン1重量部当り水約10〜11重量部
及び酢酸エチル約4〜6重量部からなる溶媒混
合物中の、塩基2.5〜2.7モル当量を含有する懸
濁液に、約12〜18℃で約40〜60分間に亘り、約
6.5〜8のPHを維持しながら、4−C1〜C4アル
キル−2,3−ジオキソ−1−ピペラジノカル
ボニルハライド約1.05〜1.15モル割合を添加
し;
(2) 反応混合物を約12〜18℃で約20〜30分間更に
撹拌し;
(3) 反応混合物を、工程(1)で仕込んだアンピシリ
ン1重量部当り約0.08〜0.1重量部の活性炭及
び約0.1〜0.15重量部の過助剤で処理し、そ
して得られる混合物を約12〜18℃で約15〜20分
間撹拌し;
(4) 清澄化の後、不溶性物質を、工程(1)で仕込ん
だアンピシリン1重量部当り約1.0〜1.2重量部
の水で洗浄し;
(5) 母液及び洗浄液を、工程(1)で仕込んだアンピ
シリン1重量部当り約6〜7重量部の酢酸エチ
ルと一緒にし、そして得られる混合物を約18〜
22℃に加温し、但し工程(1)及び(5)で用いた酢酸
エチルの全量は元々仕込んだアンピシリン1重
量部当り約11〜12重量部であり;
(6) 反応混合物を約18〜22℃で約2.2〜2.3のPHま
で酸性にし;
(7) 酸性にした反応混合物を約18〜22℃で約2〜
3時間撹拌した後、結晶性の遊離酸を集め;そ
して
(8) 遊離酸を、随時約13.125%(無水の遊離酸の
重量/水の容量)の濃度で水に溶解し、これに
アルカリ金属炭酸塩約1モル当量を徐々に添加
し;反応混合物を、PHが少くとも6.5に低下す
るまで約6±4℃で約3〜4時間撹拌した後、
式()の生成物のアルカリ金属塩を集める、
ことから成る好適な改良法を提供する。 The present invention also provides: (1) a suspension containing 2.5 to 2.7 molar equivalents of base in a solvent mixture consisting of about 10 to 11 parts by weight of water and about 4 to 6 parts by weight of ethyl acetate per part by weight of ampicillin; For about 40 to 60 minutes at about 12 to 18℃, about
Adding about 1.05 to 1.15 molar proportion of 4- C1 to C4 alkyl-2,3-dioxo-1-piperazinocarbonyl halide while maintaining a pH of 6.5 to 8; (2) Bringing the reaction mixture to about 12 Further stirring for about 20 to 30 minutes at ~18°C; (3) The reaction mixture was mixed with about 0.08 to 0.1 parts by weight of activated carbon and about 0.1 to 0.15 parts by weight of supercharging per 1 part by weight of ampicillin charged in step (1). and stirring the resulting mixture at about 12-18° C. for about 15-20 minutes; (4) After clarification, the insoluble material is reduced to about 1.0% per part by weight of ampicillin charged in step (1). (5) Combine the mother liquor and wash liquor with about 6 to 7 parts by weight of ethyl acetate per part by weight of ampicillin charged in step (1), and mix the resulting mixture with about 18 parts by weight of water; ~
Warm to 22°C, provided that the total amount of ethyl acetate used in steps (1) and (5) is about 11 to 12 parts by weight per 1 part by weight of ampicillin originally charged; Acidify to a pH of about 2.2-2.3 at 22°C; (7) Acidify the acidified reaction mixture to a pH of about 2-2.3 at about 18-22°C;
After stirring for 3 hours, the crystalline free acid is collected; and (8) the free acid is then dissolved in water at a concentration of about 13.125% (weight of anhydrous free acid/volume of water) and alkali metal added thereto. About 1 molar equivalent of carbonate is slowly added; the reaction mixture is stirred at about 6±4° C. for about 3 to 4 hours until the pH drops to at least 6.5, and then
A preferred improved method is provided comprising: collecting the alkali metal salt of the product of formula ().
本発明を更に理解するために、次の実施例を示
す。しかしこれは本発明を制限するものでなく、
実施例中のすべての部は断らない限り重量による
ものとする。 In order to further understand the invention, the following examples are presented. However, this does not limit the invention;
All parts in the examples are by weight unless otherwise specified.
実施例 1
6−〔D(−)−α−(4−エチル−2,3−ジオ
キソ−1−ピペラジノカルボニルアミノ)フエ
ニルアセトアミド〕ペニシラン酸一水和物の製
造
アンピシリン三水和物27.00g〔純無水のアン
ピシリンの22.86g(0.0654モル)に相当〕、炭酸
水素ナトリウム14.50g(0.1726モル)、水238g
及び酢酸エチル119gの撹拌スラリーに、6以上
のPH及び15±2℃の温度が維持できる速度で4−
エチル−2,3−ジオキソ−1−ピペラジノカル
ボニルクロライド14.73g(0.0720モル)を添加
した。この添加の完了後、反応混合物を15±2℃
で20分間撹拌し、これに活性炭(RB型活性炭;
Pittsburgh Coke and Chemical Co.)2.1g及び
過助剤(Hyflo
Super−Cel;Johns−
Manville Sales Corp.)3.0gを添加した。この
混合物を更に10分間撹拌し、固体を過によつて
除去し、水26gで洗浄した。液及び洗浄液を一
緒にし、次いで酢酸エチル142.5gと混合した。
得られた混合物の温度を20〜22℃に調節し、2N
塩酸の添加によつてPHを2.3に調節した。この酸
性にした混合物を20〜22℃で2.5時間撹拌し、結
晶性沈殿を別し、水120gで洗浄し、乾燥して
所望の生成物33.49g(理論量の95.58%)を得
た。Example 1 Production of 6-[D(-)-α-(4-ethyl-2,3-dioxo-1-piperazinocarbonylamino)phenylacetamide]penicillanic acid monohydrate Ampicillin trihydrate 27.00 g [equivalent to 22.86 g (0.0654 mol) of pure anhydrous ampicillin], 14.50 g (0.1726 mol) of sodium bicarbonate, 238 g of water
and 119 g of ethyl acetate at a rate that maintains a pH of 6 or higher and a temperature of 15 ± 2°C.
14.73 g (0.0720 mol) of ethyl-2,3-dioxo-1-piperazinocarbonyl chloride was added. After this addition is complete, heat the reaction mixture to 15±2°C.
Stir for 20 minutes and add activated carbon (RB type activated carbon;
(Pittsburgh Coke and Chemical Co.) 2.1 g and super-aid (Hyflo Super-Cel; Johns-
Manville Sales Corp.) 3.0g was added. The mixture was stirred for an additional 10 minutes and the solids were removed by filtration and washed with 26 g of water. The liquid and washing liquid were combined and then mixed with 142.5 g of ethyl acetate.
Adjust the temperature of the resulting mixture to 20-22℃ and add 2N
The pH was adjusted to 2.3 by adding hydrochloric acid. The acidified mixture was stirred for 2.5 hours at 20-22 DEG C., the crystalline precipitate was separated off, washed with 120 g of water and dried to yield 33.49 g (95.58% of theory) of the desired product.
実施例 2
6−〔D(−)−α−(4−エチル−2,3−ジオ
キソ−1−ピペラジノカルボニルアミノ)フエ
ニルアセトアミド〕ペニシラン酸のナトリウム
塩の製造
実施例1の生成物13.5g(0.025モル、無水の
遊離酸13.125gに相当)を水100mlに溶解し、こ
の6±4℃の撹拌溶液に、各々0.206gずつ10回
に分けて炭酸水素ナトリウム2.06g(0.025モル、
無水の遊離酸の15.685%W/Wに相当)を添加し
た。次いでPHが少くとも6.5に低下するまで3〜
4時間反応を継続した。反応混合物を冷過によ
つて殺菌し、アセプチツク薬ビン(asceptic
vial)中に充填し、凍結乾燥して6−〔D(−)−
α−(4−エチル−2,3−ジオキソ−1−ピペ
ラジノカルボニルアミノ)フエニルアセトアミ
ド〕ペニシラン酸のナトリウム塩の白色又は淡黄
色の結晶を得た。Example 2 Preparation of the sodium salt of 6-[D(-)-α-(4-ethyl-2,3-dioxo-1-piperazinocarbonylamino)phenylacetamide]penicillanic acid Product of Example 1 13.5 (0.025 mol, equivalent to 13.125 g of anhydrous free acid) was dissolved in 100 ml of water, and 2.06 g (0.025 mol,
(equivalent to 15.685% W/W of anhydrous free acid) was added. Then 3~ until the PH drops to at least 6.5
The reaction continued for 4 hours. The reaction mixture was sterilized by refrigeration and poured into asceptic vials.
6-[D(-)-
White or pale yellow crystals of the sodium salt of α-(4-ethyl-2,3-dioxo-1-piperazinocarbonylamino)phenylacetamide]penicillanic acid were obtained.
Claims (1)
−ピペラジノカルボニルハライドを塩基の存在下
に酢酸エチル及び水の混合物中のアンピシリンの
溶液又は懸濁液に添加して反応混合物を生成せし
め、得られる混合物を反応が完結するまで攪拌
し、反応混合物を酸性にし、そしてそれから結晶
生成物を回収することから成る6−[D(−)−α
−(4−C1〜C4アルキル−2,3−ジオキソ−1
−ピペラジノカルボニルアミノ)−フエニルアセ
トアミド]ペニシラン酸の製造方法において、 (a) アンピシリン1重量部当り水約9〜12重量部
及び酢酸エチル約0.5〜8重量部からなる溶媒
混合物中の、約1モル割合のアンピシリン及び
適当量の適当な塩基の攪拌懸濁液に、約10〜25
℃で少くとも30分間に亘り、約6〜8.3のPHを
維持しながら、4−C1〜C4アルキル−2,3
−ジオキソ−1−ピペラジノカルボニルハライ
ド約1〜1.5モル割合を添加し; (b) 工程(a)の4−C1〜C4アルキル−2,3−ジ
オキソ−1−ピペラジノカルボニルハライドの
添加が完了したら反応混合物を約10〜25℃で少
くとも15分間更に攪拌し; (c) この反応混合物に、工程(a)で仕込んだアンピ
シリン1重量部当りそれぞれ約0.05〜0.2重量
部の活性炭及び過助剤を添加し、そして得ら
れる混合物を約10〜25℃で少くとも10分間攪拌
し; (d) 得られる混合物を清澄化させ、そして工程(a)
で仕込んだアンピシリン1重量部当り約0.6〜
25重量部の水で不溶性物質を洗浄し; (e) 工程(d)で得た母液及び洗浄液を、工程(a)で仕
込んだアンピシリン1重量部当り約2〜12.5重
量部の酢酸エチルと一緒にし、但し工程(a)及び
(e)で使用する酢酸エチルの全量は該アンピシリ
ン1重量部当り約10〜13重量部であり、そして
得られる混合物を約15〜25℃に加温し; (f) 工程(e)で得た混合物を約15〜25℃で約2.0〜
2.5のPHまで酸性にし;そして (g) 酸性にした混合物を約15〜25℃で少くとも1
時間攪拌した後、得られる結晶性の遊離酸を回
収し;そして (h) この遊離酸を随時製薬学的に許容しうる塩に
塩化する、 ことを特徴とする6−[D(−)−α−(4−C1〜
C4アルキル−2,3−ジオキソ−1−ピペラジ
ノカルボニルアミノ)−フエニルアセトアミド]
ペニシラン酸の製造方法。 2 (a) アンピシリン1重量部当り水約10〜11重
量部及び酢酸エチル約4〜6重量部からなる溶
媒混合物中の、塩基2.5〜2.7モル当量を含有す
る懸濁液に、約12〜18℃で約40〜60分間に亘
り、約6.5〜8のPHを維持しながら、4−C1〜
C4アルキル−2,3−ジオキソ−1−ピペラ
ジノカルボニルハライド約1.05〜1.15モル割合
を添加し; (b) 反応混合物を約12〜18℃で約20〜30分間更に
攪拌し; (c) 反応混合物を、工程(a)で仕込んだアンピシリ
ン1重量部当り約0.08〜0.1重量部の活性炭及
び約0.1〜0.15重量部の過助剤で処理し、そ
して得られる混合物を約12〜18℃で約15〜20分
間攪拌し; (d) 不溶性物質を、工程(a)で仕込んだアンピシリ
ン1重量部当り約1.0〜1.2重量部の水で洗浄
し; (e) 母液及び洗浄液を、工程(a)で仕込んだアンピ
シリン1重量部当り約6〜7重量部の酢酸エチ
ルと一縮にし、そして得られる混合物を約18〜
22℃に加温し、但し工程(a)及び(e)で用いた酢酸
エチルの全量は該アンピシリン1重量部当り約
11〜12重量部であり; (f) 反応混合物を約18〜22℃で約2.2〜2.3のPHま
で酸性にし; (g) 酸性にした反応混合物を約18〜22℃で約2〜
3時間攪拌した後、結晶性の遊離酸を集め、水
洗しそして乾燥し;そして (h) 遊離酸を、随時水1当り無水の遊離酸約
131.25gの濃度で水に溶解し、これにアルカリ
金属炭酸塩約1モル当量を徐々に添加し;反応
混合物をPHが少くとも6.5に低下するまで約6
±4℃で約3〜4時間攪拌し、 次いで式()の生成物のアルカリ金属塩を集
める、 ことを特徴とする特許請求の範囲第1項記載の方
法。 3 4−C1〜C4アルキル−2,3−ジオキソ−
1−ピペラジノカルボニルハライドが4−C1〜
C4アルキル−2,3−ジオキソ−1−ピペラジ
ノカルボニルクロライドである特許請求の範囲第
1又は2項記載の方法。 4 4−C1〜C4アルキル−2,3−ジオキソ−
1−ピペラジノカルボニルハライドが4−エチル
−2,3−ジオキソ−1−ピペラジノカルボニル
クロライドである特許請求の範囲第1又は第2項
記載の方法。 5 生成物をナトリウム塩に転化する特許請求の
範囲第1又は2項記載の方法。[Claims] 1 4-C 1 -C 4 alkyl-2,3-oxo-1
- adding piperazinocarbonyl halide to a solution or suspension of ampicillin in a mixture of ethyl acetate and water in the presence of a base to form a reaction mixture; stirring the resulting mixture until the reaction is complete; 6-[D(-)-α consisting of acidifying the mixture and recovering the crystalline product therefrom.
-(4-C 1 -C 4 alkyl-2,3-dioxo-1
-piperazinocarbonylamino)-phenylacetamide] penicillanic acid, comprising: (a) in a solvent mixture consisting of about 9 to 12 parts by weight of water and about 0.5 to 8 parts by weight of ethyl acetate per 1 part by weight of ampicillin; In a stirred suspension of about 1 molar proportion of ampicillin and an appropriate amount of a suitable base, about 10 to 25
4-C1 to C4 alkyl -2,3 while maintaining a pH of about 6 to 8.3 for at least 30 minutes at °C.
-adding about 1 to 1.5 molar proportion of dioxo-1-piperazinocarbonyl halide; (b) the 4- C1 to C4 alkyl-2,3-dioxo-1-piperazinocarbonyl halide of step (a); (c) Add to the reaction mixture about 0.05 to 0.2 parts by weight of each for each part by weight of ampicillin charged in step (a). Activated carbon and superaid are added and the resulting mixture is stirred for at least 10 minutes at about 10-25°C; (d) the resulting mixture is clarified and step (a)
Approximately 0.6 to 1 part by weight of ampicillin prepared with
washing the insoluble material with 25 parts by weight of water; (e) combining the mother liquor and wash liquor obtained in step (d) with about 2 to 12.5 parts by weight of ethyl acetate per part by weight of ampicillin charged in step (a); However, steps (a) and
The total amount of ethyl acetate used in step (e) is about 10 to 13 parts by weight per part of said ampicillin, and the resulting mixture is heated to about 15 to 25°C; (f) obtained in step (e). The mixture was heated to about 2.0 to 2.0℃ at about 15 to 25℃.
acidified to a pH of 2.5; and (g) the acidified mixture at about 15-25°C to a pH of at least 1
6-[D(-)-, characterized in that after stirring for a period of time, the resulting crystalline free acid is recovered; and (h) the free acid is optionally salified to a pharmaceutically acceptable salt. α−(4−C 1 ~
C 4 alkyl-2,3-dioxo-1-piperazinocarbonylamino)-phenylacetamide]
Method for producing penicillanic acid. 2 (a) in a suspension containing 2.5 to 2.7 molar equivalents of base in a solvent mixture consisting of about 10 to 11 parts by weight of water and about 4 to 6 parts by weight of ethyl acetate per part by weight of ampicillin. ℃ for about 40 to 60 minutes while maintaining a pH of about 6.5 to 8 .
Adding about 1.05-1.15 molar proportion of C4 alkyl-2,3-dioxo-1-piperazinocarbonyl halide; (b) further stirring the reaction mixture at about 12-18°C for about 20-30 minutes; (c ) The reaction mixture is treated with about 0.08 to 0.1 parts by weight of activated carbon and about 0.1 to 0.15 parts by weight of super-aid per part by weight of ampicillin charged in step (a), and the resulting mixture is heated to about 12 to 18°C. (d) Wash the insoluble material with about 1.0 to 1.2 parts by weight of water per part by weight of ampicillin charged in step (a); (e) Add the mother liquor and washing solution to step ( 1 part by weight of ampicillin charged in a) is condensed with about 6 to 7 parts by weight of ethyl acetate, and the resulting mixture is mixed with about 18 to 7 parts by weight of ethyl acetate.
Warm to 22°C, provided that the total amount of ethyl acetate used in steps (a) and (e) is approximately 1 part by weight of the ampicillin.
(f) acidifying the reaction mixture to a pH of about 2.2 to 2.3 at about 18 to 22°C; (g) acidifying the acidified reaction mixture to a pH of about 2 to 2.3 at about 18 to 22°C;
After stirring for 3 hours, the crystalline free acid is collected, washed with water and dried; and (h) the free acid is optionally mixed in a proportion of about 10% of the anhydrous free acid per 1 part of water.
About 1 molar equivalent of alkali metal carbonate is gradually added to the water at a concentration of 131.25 g;
2. A process according to claim 1, characterized in that: stirring for about 3 to 4 hours at ±4° C. and then collecting the alkali metal salt of the product of formula (). 3 4-C 1 -C 4 alkyl-2,3-dioxo-
1-piperazinocarbonyl halide is 4-C 1 ~
The method according to claim 1 or 2, which is C 4 alkyl-2,3-dioxo-1-piperazinocarbonyl chloride. 4 4-C 1 -C 4 alkyl-2,3-dioxo-
3. The method according to claim 1 or 2, wherein the 1-piperazinocarbonyl halide is 4-ethyl-2,3-dioxo-1-piperazinocarbonyl chloride. 5. A method according to claim 1 or 2, wherein the product is converted into a sodium salt.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24875481A | 1981-03-30 | 1981-03-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS57165391A JPS57165391A (en) | 1982-10-12 |
| JPH0331716B2 true JPH0331716B2 (en) | 1991-05-08 |
Family
ID=22940531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57026170A Granted JPS57165391A (en) | 1981-03-30 | 1982-02-22 | Novel manufacture of 6-(d(-)-alpha-(4- c1-c4 alkyl-2,3-dioxo-1-piperadinocarbonylamino) phenylacetamide)penicillanic acid |
Country Status (23)
| Country | Link |
|---|---|
| JP (1) | JPS57165391A (en) |
| AT (1) | AT381706B (en) |
| AU (1) | AU544896B2 (en) |
| BE (1) | BE892586A (en) |
| CA (1) | CA1200239A (en) |
| CH (1) | CH654309A5 (en) |
| DE (1) | DE3208506A1 (en) |
| DK (1) | DK161079C (en) |
| ES (1) | ES509424A0 (en) |
| FR (1) | FR2502623A1 (en) |
| GB (1) | GB2095661B (en) |
| GR (1) | GR76054B (en) |
| HK (1) | HK23590A (en) |
| IE (1) | IE52907B1 (en) |
| IL (1) | IL64981A (en) |
| IT (1) | IT1148130B (en) |
| LU (1) | LU84036A1 (en) |
| NL (2) | NL192453A (en) |
| NZ (1) | NZ199869A (en) |
| PH (1) | PH19765A (en) |
| PL (1) | PL235508A1 (en) |
| SE (1) | SE452767B (en) |
| ZA (1) | ZA82674B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BG46664A1 (en) * | 1985-08-16 | 1990-02-15 | Druzhestven N Izsledovatelski | Method for preparing of 6- /d (-)- alpha- (4- ethyl- 2, 3- dioxo- 1- piperazine carbonylamino)- phenylacetamido/- penicillanic acid |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4112090A (en) * | 1974-05-09 | 1978-09-05 | Toyama Chemical Co., Ltd. | Novel penicillins and cephalosporins and process for producing the same |
| US4087424A (en) * | 1974-05-09 | 1978-05-02 | Toyama Chemical Co., Ltd. | Novel penicillins and cephalosporins and process for producing the same |
| IL47168A (en) * | 1974-05-09 | 1979-07-25 | Toyama Chemical Co Ltd | Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same |
-
1982
- 1982-01-28 CA CA000395121A patent/CA1200239A/en not_active Expired
- 1982-01-29 GB GB8202662A patent/GB2095661B/en not_active Expired
- 1982-01-29 AU AU79964/82A patent/AU544896B2/en not_active Expired
- 1982-02-02 ZA ZA82674A patent/ZA82674B/en unknown
- 1982-02-03 GR GR67199A patent/GR76054B/el unknown
- 1982-02-04 DK DK048282A patent/DK161079C/en active
- 1982-02-08 ES ES509424A patent/ES509424A0/en active Granted
- 1982-02-11 IL IL64981A patent/IL64981A/en unknown
- 1982-02-17 PH PH26877A patent/PH19765A/en unknown
- 1982-02-22 JP JP57026170A patent/JPS57165391A/en active Granted
- 1982-03-01 NZ NZ199869A patent/NZ199869A/en unknown
- 1982-03-09 DE DE19823208506 patent/DE3208506A1/en active Granted
- 1982-03-09 AT AT0093082A patent/AT381706B/en not_active IP Right Cessation
- 1982-03-10 IT IT47962/82A patent/IT1148130B/en active
- 1982-03-17 FR FR8204497A patent/FR2502623A1/en active Granted
- 1982-03-18 PL PL23550882A patent/PL235508A1/xx unknown
- 1982-03-22 BE BE0/207631A patent/BE892586A/en not_active IP Right Cessation
- 1982-03-24 LU LU84036A patent/LU84036A1/en unknown
- 1982-03-26 CH CH1898/82A patent/CH654309A5/en not_active IP Right Cessation
- 1982-03-29 NL NL192453D patent/NL192453A/xx not_active IP Right Cessation
- 1982-03-29 NL NL8201301A patent/NL192453C/en not_active IP Right Cessation
- 1982-03-29 SE SE8201998A patent/SE452767B/en not_active IP Right Cessation
- 1982-03-29 IE IE746/82A patent/IE52907B1/en not_active IP Right Cessation
-
1990
- 1990-03-29 HK HK235/90A patent/HK23590A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4504657A (en) | Cephadroxil monohydrate | |
| JPH0331716B2 (en) | ||
| JPS59130889A (en) | Novel cephalosporin intermediate | |
| JPS62103089A (en) | Manufacture of 6-d-alpha- (4-ethyl-2,3-dioxo-1-piperazinocarbonylamino) -phenylacetamido-penicillanic acid | |
| US4610822A (en) | Process for preparing 6-[D(-)-α-(4-C1 -C4)-alkyl-2,3-dioxo-1-piperazinocarbonylamino)phenylacetamido]penicillanic acids | |
| JP2003506444A (en) | Preparation of thiazole derivatives | |
| KR850000611B1 (en) | Process for preparing 6-(d(-)-alpha-(4-c1 c4 alkyl-2,3-dioxo-1-piperazino-carbonylamino)-phenylacetamido)penicillanic acid | |
| JP2001247529A (en) | Method for producing α-amino acid amide | |
| JP3523661B2 (en) | Method for purifying 2-alkyl-4-halogeno-5-formylimidazole | |
| JPH0761957A (en) | Production of n-mixed saturated fatty acid acyl neutral amino acid | |
| JPH03148282A (en) | Production of cephalosporanic acid derivative | |
| JPS5993059A (en) | Production method of cytosines | |
| JP2714868B2 (en) | Method for producing 2-methylthiosemicarbazide | |
| EP0106369A2 (en) | Purification of ceforanide | |
| JP3957005B2 (en) | Method for producing 2-amino-6-iodopurine | |
| JPH1180072A (en) | Production of highly pure lower saturated aliphatic carboxylic acid hydroxylamine | |
| JPH06166655A (en) | Production of tetramethoxymethylbenzaldehyde | |
| JPH06256346A (en) | Production of isoguanine | |
| JPS60139695A (en) | Chlorocefadroxil monohydride | |
| KR20040015025A (en) | Method for producing a phenylene-bis-benzimidazole-tetrasulfonic acid disodium salt | |
| JPS62298565A (en) | Production of l-alpha-methyldopa | |
| JPH0256459A (en) | Production of p-toluenesulfonyl acetic acid | |
| JPH0256460A (en) | Production of p-toluenesulfonyl acetic acid | |
| JPS6270346A (en) | Production of threo-1-phenyl-2-amino-1-propanol derivative | |
| JPH0859585A (en) | Process for producing α-acetamidocinnamic acid |